Random good picture Not show

1. Most studies have, however, reported that cyclosporin A comparably inhibited renal prostaglandin formation.

2. Several case reports have suggested that oral cyclosporin is effective in inducing clinical and endoscopic remission.

3. Significant cyclosporin toxicity during prolonged treatment is minimal and does not appear to be a limiting factor at this dose of cyclosporin.

4. Infections appeared to occur more commonly in the cyclosporin group, although the difference was not statistically significant.

5. Treatment with cyclosporin A in the doses used did not inhibit eicosanoid formation by the pancreatic tissue ex vivo.

5. Sentencedict.com is a online sentence dictionary, on which you can find excellent sentences for a large number of words.

6. In addition, one patient receiving cyclosporin was excluded because treatment was discontinued after only three months.

7. Cyclosporin treatment was stopped but the patient continued to deteriorate and died from sepsis and shock in spite of antibiotic treatment.

8. Other studies suggest that cyclosporin is of therapeutic value in ulcerative colitis, but there have been no controlled trials.

9. All five patients receiving oral cyclosporin had a remission but relapse occurred within three months of discontinuing the drug.

10. Ten days after cyclosporin intoxication he was discharged from the ICU.

11. Cyclosporin A produced protective effects against mouse Schistosomiasis japonica in several ways.

12. This paper reports that Cyclosporin A not only killed Schistosomula and adult of S. japonicum in hepatic portal system phase, but also stunted the growth of Schistosomula.

13. Methods. Cyclosporin was administered orally with and without a single oral dose of St. John's Wort.

14. Objective To study the pharmacokinetics of cyclosporin A (CsA) with or without combination of berberine hydrochloride (Ber) in renal transplantation recipients.

15. Objective To study the ameliorative effect of cyclosporin A on cerebral ischemia reperfusion lesion.

16. Conclusion Cyclosporin A in ophthalmology in the wider range of applications, how to develop new carrier materials, reducing its toxic side effects, that the drug research.

17. AIM: To observe the effect of praziquantel cyclosporin A combination on murine schistosomal hepatic fibrosis.

18. OBJECTIVE: To study the pharmacokinetics of cyclosporin A (CsA) with or without combination of berberine chloride(Ber)in renal transplanted recipients.

19. Various methods for synthesis of immunogen of cyclosporin A were discussed and brief introductions of some aspects were given.

20. Recurrent oral and vaginal yeast infections occurred in two patients receiving cyclosporin and oral thrush occurred in one patient receiving placebo.

21. The aim of this study was to examine whether endogenous eicosanoids play a role in controlling cyclosporin A induced toxicity.

22. These infections cleared up after standard treatment and temporary discontinuation of the cyclosporin.

23. In all instances the toxicity was easily reversed by reducing the cyclosporin dose.

24. Much of the improvement in survival has resulted from the now routine use of cyclosporin as an immunosuppressive agent.

25. Concern about nephrotoxicity has been the major factor limiting more widespread investigational use of cyclosporin in ulcerative colitis.

26. This study attempted to use a single dose protocol to investigate whether rat and pig models could demonstrate interaction between St. John's Wort and cyclosporin in humans.

27. The patient was a 27 year old man with a history of bone marrow transplant for myelodysplastic syndrome who had generalized seizures while undergoing treatment with cyclosporin A.

28. Objective To evaluate the safety measures for children with severe aplastic anemia, treated by the combination of human immunoglobulin and cyclosporin A.

29. The study was aimed to explore clinical result of cyclosporin A (CsA) and androgens for treatment of myelodysplastic syndrome (MDS) with refractory anemia.

30. Objectives. Clinical problems which arise from the interaction of St. John's Wort with cyclosporin have attracted much attention.